Ferozsons Laboratories Limited

FEROZ

PK0005201014

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
220.2 ^PKR	-0.55%		-4.81%	-0.21%

Feb. 29	Ferozsons Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	Ferozsons Laboratories Limited Reports Earnings Results for the First Quarter Ended September 30, 2023	CI

Ferozsons Laboratories Limited Approves an Interim Cash Dividend for the Six Months Ended 31 December 2019

February 28, 2020 at 06:17 am EST

The board of directors of Ferozsons Laboratories Limited in its meeting held on 28 February 2020 has approved an interim cash dividend of PKR Nil per share (31 December 2018: PKR 2 per share) amounting to PKR Nil (31 December 2018: PKR 60,373,682) for the year ending 30 June 2020.

Latest news about Ferozsons Laboratories Limited

Ferozsons Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 28	CI
Ferozsons Laboratories Limited Reports Earnings Results for the First Quarter Ended September 30, 2023	23-10-29	CI
Ferozsons Laboratories Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-10-07	CI
Ferozsons Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-04-26	CI
Ferozsons Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-28	CI
Ferozsons Laboratories Limited Reports Earnings Results for the First Quarter Ended September 30, 2022	22-10-31	CI
Ferozsons Laboratories Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-08	CI
Ferozsons Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-04-25	CI
Ferozsons Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-02-06	CI
Ferozsons Laboratories Limited Reports Earnings Results for the First Quarter Ended September 30, 2021	21-10-26	CI
Ferozsons Laboratories Limited Reports Earnings Results for the Full Year Ended June 30, 2021	21-08-31	CI
Ferozsons Laboratories Limited Reports Earnings Results for the Third Quarter Ended March 31, 2021	21-04-26	CI
Ferozsons Laboratories Limited Reports Earnings Results for the Second Quarter Ended December 31, 2020	21-01-29	CI
Ferozsons Laboratories Limited Proposes the Final Cash Dividend for the Year Ended 30 June 2020	20-10-04	CI
Ferozsons Laboratories Limited Reports Earnings Results for the Full Year Ended June 30, 2020	20-09-24	CI
Gilead Sciences : India sees record 49,000 new coronavirus cases, drug shortages in places	20-07-24	RE
Pakistan's Ferozsons to begin producing COVID-19 drug remdesivir	20-05-15	RE
Gilead Sciences, Inc. Signs Licensing Agreements with Cipla Limited, Hetero Labs Limited, Jubilant Life Sciences Limited, Mylan, Inc. and Ferozsons Laboratories Limited to Manufacture and Distribute Remdesivir in 127 Countries	20-05-13	CI
Mylan N : Gilead ties up with generic drugmakers for COVID-19 drug supply	20-05-12	RE
Mylan N : Gilead ties up with generic drugmakers for COVID-19 drug supply	20-05-12	RE
Ferozsons Laboratories Limited Reports Earnings Results for the Third Quarter Ended March 31, 2020	20-04-29	CI
Ferozsons Laboratories Limited Approves an Interim Cash Dividend for the Six Months Ended 31 December 2019	20-02-28	CI
Ferozsons Laboratories Limited Reports Earnings Results for the Second Quarter Ended December 31, 2019	20-02-28	CI
Ferozsons Laboratories Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2019	19-10-25	CI
Ferozsons Laboratories Limited Announces Final Cash Dividend	19-09-23	CI

Chart Ferozsons Laboratories Limited

Duration

Period

More charts

Company Profile

Ferozsons Laboratories Limited is a Pakistan-based holding company. The Company is primarily engaged in the importing, manufacturing and sale of pharmaceutical products and medical devices. The Company possesses brands in the areas of gastroenterology, hepatology, cardiology, and oncology, with an emerging presence in endocrinology as well as mother and child health the diabetes space. The Company offers a range of medical devices in the areas of cardiology, electrophysiology, endoscopy, gastroenterology, pulmonology, urology, and peripheral interventions. Its product portfolio includes pharmaceuticals, medical technologies, and export. The Companyâs export markets are spread across Asia, Africa, and the Central Asian region. The Company's subsidiaries include BF Biosciences Limited, which is engaged in the import, manufacturing, and sale of pharmaceutical products and Farmacia, which is engaged in the sale and distribution of medicines and other related products.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

220.2 PKR

Average target price

325 PKR

Spread / Average Target

+47.61%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FEROZSONS LABORATORIES LIMITED	-0.21%	34.37M
ELI LILLY AND COMPANY	+33.25%	704B
NOVO NORDISK A/S	+28.59%	577B
JOHNSON & JOHNSON	-3.55%	348B
MERCK & CO., INC.	+18.16%	327B
ABBVIE INC.	+4.36%	288B
ASTRAZENECA PLC	+14.81%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-3.69%	147B

Other Pharmaceuticals